单位：[1]Data and Project Management Unit, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China[2]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[3]National Clinical Research Center for Respiratory Disease, Beijing, China[4]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China[5]Beijing University of Chinese Medicine, Beijing, China[6]Peking University Health Science Center, Capital Medical University, Beijing, China
Objective To conduct a survey of diagnostic facility and therapeutic capability of Pulmonary thromboembolism (PE) in 90 hospitals throughout China. Method It was a cross-sectional study among the participating hospitals of the National Key Research & Development Program of China-the Precision Research of StandardizedManagement and Application of Pulmonary Thromboembolismto obtain the equipment and application of radiological facility to diagnose PE, laboratory tests for thrombophilia, coagulation function and the availability of anticoagulants and thrombolysis agents. Results CT pulmonary arteriography is capable in all 90 hospitals, 71.11% of the hospitals could perform ventilation/perfusion scintigraphy, 24.44% of the hospitals do not routinely perform right heart evaluation by echocardiography. Protein C and protein S activity can be detected in half of the hospitals and warfarin pharmacogenomics tests can be conducted in 40 hospitals. Immune turbidimetry was used as the detection method of D-dimer in 72.37% hospitals. About 81.11% of participating hospitals were equipped with new novel oral anticoagulants, all of which were equipped with Rivaroxaban. Conclusion The hospitals are capable for standardized diagnosis and management PE, while the capability of precise stratification, coagulation function tests, thrombophilia screening and pharmacogenomics requires further improvement.
基金：
the National Key R&D Program of China [2016YFC0905600] Funding Source: Medline
第一作者单位：[1]Data and Project Management Unit, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China[2]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[3]National Clinical Research Center for Respiratory Disease, Beijing, China
通讯作者：
通讯机构：[2]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China[3]National Clinical Research Center for Respiratory Disease, Beijing, China[4]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China[6]Peking University Health Science Center, Capital Medical University, Beijing, China[*1]Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.
推荐引用方式(GB/T 7714)：
Wang Dingyi,Shao Xiang,Lei Jieping,et al.A survey of precision diagnosis and management capacity of pulmonary embolism in 90 hospitals of China[J].CLINICAL RESPIRATORY JOURNAL.2020,14(7):638-644.doi:10.1111/crj.13178.
APA：
Wang, Dingyi,Shao, Xiang,Lei, Jieping&Zhai, Zhenguo.(2020).A survey of precision diagnosis and management capacity of pulmonary embolism in 90 hospitals of China.CLINICAL RESPIRATORY JOURNAL,14,(7)
MLA：
Wang, Dingyi,et al."A survey of precision diagnosis and management capacity of pulmonary embolism in 90 hospitals of China".CLINICAL RESPIRATORY JOURNAL 14..7(2020):638-644
